Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;15(2):141-148.
doi: 10.1007/s11899-020-00571-8.

Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults

Nicole Kucine  1
Affiliations
Review

Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults

Nicole Kucine. Curr Hematol Malig Rep. 2020 Apr.

Abstract

Purpose of review: Myeloproliferative neoplasms are traditionally seen in older adults, making them poorly understood in younger patients. Clinical presentation, genetic landscape, outcomes, and best management practices are inadequately described in this group. Over the past decade, more research has focused on younger patients, and this paper seeks to review and describe the current status of the field.

Recent findings: A recent review analyzed the available pediatric MPN literature and highlighted the paucity of published data. Pediatric patients showed lower rates of the common mutations found in adults, thrombotic events, and disease transformation to myelofibrosis and acute leukemia. A number of centers have recently shared their experience with young adult patients. Better survival outcomes were confirmed for young adult patients compared to older patients. There is still much to learn about myeloproliferative neoplasms in pediatric and young adult patients, but currently available data showing better outcomes is reassuring.

Keywords: Essential thrombocytosis; Pediatric; Polycythemia vera; Primary myelofibrosis; Young adult.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Dr. Kucine declares no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosince kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–97. DOI: 10.1016/j.ccr.2005.03.023. - DOI - PubMed
    1. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472–6.CALR paper. DOI: 10.1182/blood-200604-018879 - DOI - PubMed
    1. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New England Journal of Medicine. 2013;369(25):2391–405. doi:10.1056/NEJMoa1312542. - DOI - PMC - PubMed
    1. Nangalia J, Green TR. The evolving genomic landscape of myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2014;2014(1):287–96. doi: 10.1182/asheducation-2014.1.287. - DOI - PubMed
    1. Barbui T How to manage children and young adults with myeloproliferative neoplasms. Leukemia. 2012. July;26(7):1452–7. doi: 10.1038/leu.2012.12 - DOI - PubMed

Publication types

Substances